Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

onkovis gmbh (8111905) - bortezomibanhydrid - pulver zur herstellung einer injektionslösung - teil 1 - pulver zur herstellung einer injektionslösung; bortezomibanhydrid (43230) 3,336 milligramm

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

denk pharma gmbh & co. kg (8128863) - bortezomibanhydrid - pulver zur herstellung einer injektionslösung - teil 1 - pulver zur herstellung einer injektionslösung; bortezomibanhydrid (43230) 3,366 milligramm

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

baset pharma gmbh - propyphenazon, benzyl[(rs)-(hydroxy)(phenyl)acetat], paracetamol - manteltabletten - propyphenazon 275.mg; benzyl[(rs)-(hydroxy)(phenyl)acetat] 30.mg; paracetamol 165.mg

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

helm pharmaceuticals gmbh - eisen(ii)-gluconat (ph.eur) - manteltabletten - eisen(ii)-gluconat (ph.eur) 300.mg

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

helm pharmaceuticals gmbh - eisen(ii)-sulfat - manteltabletten - eisen(ii)-sulfat 192.31mg

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

helm pharmaceuticals gmbh - thiaminchloridhydrochlorid, calciumpantothenat, riboflavin, nicotinamid, pyridoxinhydrochlorid, colecalciferol, retinolacetat - manteltabletten - thiaminchloridhydrochlorid 0.5mg; calciumpantothenat 1.mg; riboflavin 0.1mg; nicotinamid 5.mg; pyridoxinhydrochlorid 0.1mg; colecalciferol 200.i.e.; retinolacetat 2000.i.e.

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

rosen-apotheke harro braun - propyphenazon, benzyl[(rs)-(hydroxy)(phenyl)acetat], paracetamol - manteltabletten - propyphenazon 275.mg; benzyl[(rs)-(hydroxy)(phenyl)acetat] 30.mg; paracetamol 165.mg

Union européenne - allemand - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

apotheke iffezheim ursula zimmermann (0058494) - propyphenazon; benzyl[(rs)-(hydroxy)(phenyl)acetat]; paracetamol - manteltabletten - propyphenazon (908) 275 milligramm; benzyl[(rs)-(hydroxy)(phenyl)acetat] (1076) 30 milligramm; paracetamol (1212) 165 milligramm

Allemagne - allemand - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

cirksena-apotheke helga obes (0031532) - propyphenazon; benzyl[(rs)-(hydroxy)(phenyl)acetat]; paracetamol - manteltabletten - propyphenazon (908) 275 milligramm; benzyl[(rs)-(hydroxy)(phenyl)acetat] (1076) 30 milligramm; paracetamol (1212) 165 milligramm